Advances in systemic therapy for HER2-positive metastatic breast cancer
被引:35
|
作者:
Morrow, Phuong Khanh H.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
Morrow, Phuong Khanh H.
[1
]
Zambrana, Francisco
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
Zambrana, Francisco
[1
]
Esteva, Francisco J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
Esteva, Francisco J.
[1
]
机构:
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
Human epidermal growth factor receptor (HER) 2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastuzumab was used beyond the first-line setting because of multiple mechanisms of resistance. Studies have demonstrated the clinical utility of continuing trastuzumab beyond progression, and further trials to explore this concept are ongoing. New tyrosine kinase inhibitors, monoclonal antibodies, PTEN (phosphatase and tensin homolog) pathway regulators, HER2 antibody-drug conjugates, and inhibitors of heat shock protein-90 are being evaluated to determine whether they may have a role to play in treating trastuzumab-resistant metastatic breast cancer.
机构:
Erzincan Univ, Fac Med, Dept Internal Med, Med Oncol, Erzincan, Turkey
A Yurtaslan Ankara Oncol Traning & Res Hosp, Dept Med Oncol, Ankara, TurkeyErzincan Univ, Fac Med, Dept Internal Med, Med Oncol, Erzincan, Turkey
机构:
European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Univ Milan, Dept Oncol & Hematol, Milan, ItalyEuropean Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Tarantino, Paolo
Morganti, Stefania
论文数: 0引用数: 0
h-index: 0
机构:
European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Univ Milan, Dept Oncol & Hematol, Milan, ItalyEuropean Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Morganti, Stefania
Uliano, Jacopo
论文数: 0引用数: 0
h-index: 0
机构:
European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Univ Milan, Dept Oncol & Hematol, Milan, ItalyEuropean Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Uliano, Jacopo
Giugliano, Federica
论文数: 0引用数: 0
h-index: 0
机构:
European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Univ Milan, Dept Oncol & Hematol, Milan, ItalyEuropean Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Giugliano, Federica
论文数: 引用数:
h-index:
机构:
Crimini, Edoardo
Curigliano, Giuseppe
论文数: 0引用数: 0
h-index: 0
机构:
European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
Univ Milan, Dept Oncol & Hematol, Milan, ItalyEuropean Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, I-20141 Milan, Italy
机构:
Susan F. Smith Center for Women’s Cancers, Breast Oncology Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, 02215, MASusan F. Smith Center for Women’s Cancers, Breast Oncology Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, 02215, MA